Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript

With several of them launching one to two years before that. So I think ’24, late ’24, ’25, ’26, ’27 is where we’re really going to see these products growing very nicely, following what we’ve seen in the past, which has been, maybe a 2.5 to three year to PKI conversion. So definitely going to be a very nice addition to the continued contributions from the Wave 1 and Wave 2 products, but adding four new very attractive royalty revenue streams in ’23, ’24, ’25 and then onto ’27 and beyond.

Mitchell Kapoor: Great. Thank you. And on the centric new date for potential approval, is that something more narrow that you’ll have a timeline on as we get closer to that? Or do we have an assigned date at this point?

Helen Torley: Yes. As far as we’re aware versus not communicated any assigned date, what they did state was the filing will go in, by year-end this year and assuming a standard 10 month review time. Mitch, I mean, we take it into, let’s say the September-October timeframe. But Roche has not communicated anything about that as yet.

Mitchell Kapoor: Okay, great. Thank you all very much.

Helen Torley: Thank you.

Operator: That is all the time we have for the question-and-answer session. This will conclude today’s conference call. We thank you for joining. You may now disconnect your lines.